Jupiter Neurosciences Inc
JUNS0.599USD
-0.016-2.65%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
20.56MMarket Cap
LossP/E TTM
More Details of Jupiter Neurosciences Inc Company
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Jupiter Neurosciences Inc Info
Ticker SymbolJUNS
Company nameJupiter Neurosciences Inc
IPO dateDec 03, 2024
CEORosen (Christer)
Number of employees4
Security typeOrdinary Share
Fiscal year-endDec 03
Address1001 North US HWY 1, Suite 504
CityPALM BEACH GARDENS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33477
Phone15614066154
Websitehttps://jupiterneurosciences.com/
Ticker SymbolJUNS
IPO dateDec 03, 2024
CEORosen (Christer)
Company Executives of Jupiter Neurosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.08M
--
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
--
Ms. Allison W. Brady
Ms. Allison W. Brady
Independent Director
Independent Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Independent Director
Independent Director
10.78K
--
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--
Mr. Nicholas H. Hemmerly
Mr. Nicholas H. Hemmerly
Independent Director
Independent Director
--
--
Ms. Julie Kampf
Ms. Julie Kampf
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Christer Rosen
Mr. Christer Rosen
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
11.08M
--
Mr. Alexander Gustaf Erik Rosen
Mr. Alexander Gustaf Erik Rosen
Co-Founder, Chief Administrative Officer
Co-Founder, Chief Administrative Officer
452.86K
--
Ms. Alison D Silva
Ms. Alison D Silva
President, Chief Business Officer, Director
President, Chief Business Officer, Director
112.78K
--
Ms. Allison W. Brady
Ms. Allison W. Brady
Independent Director
Independent Director
21.75K
--
Mr. Holger Weis, CPA
Mr. Holger Weis, CPA
Independent Director
Independent Director
10.78K
--
Dr. Marshall A Hayward, Ph.D.
Dr. Marshall A Hayward, Ph.D.
Co-Founder, Chief Scientific Officer, Director
Co-Founder, Chief Scientific Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Nov 28
Updated: Fri, Nov 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosen (Christer)
32.18%
Wahlestedt (Claes M.D., Ph.D.)
8.14%
Hayward (Marshall A Ph.D.)
6.91%
Brothers (Shaun P.)
4.94%
Vestor Capital Partners, LLC
2.82%
Other
45.01%
Shareholders
Shareholders
Proportion
Rosen (Christer)
32.18%
Wahlestedt (Claes M.D., Ph.D.)
8.14%
Hayward (Marshall A Ph.D.)
6.91%
Brothers (Shaun P.)
4.94%
Vestor Capital Partners, LLC
2.82%
Other
45.01%
Shareholder Types
Shareholders
Proportion
Individual Investor
54.10%
Investment Advisor
3.54%
Investment Advisor/Hedge Fund
0.37%
Research Firm
0.07%
Venture Capital
0.04%
Other
41.87%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
14
1.39M
4.03%
+1.01M
2025Q3
9
375.55K
1.09%
-18.85K
2025Q2
18
19.49M
58.89%
+1.54M
2025Q1
16
18.33M
55.39%
+383.02K
2024Q4
9
17.92M
54.13%
+14.81M
2024Q3
6
5.31M
79.52%
--
2024Q2
10
5.31M
79.52%
-11.63K
2024Q1
10
5.31M
79.52%
-11.63K
2023Q4
10
5.31M
79.52%
-11.63K
2023Q3
10
5.31M
79.52%
-11.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosen (Christer)
11.08M
32.18%
--
--
Nov 25, 2025
Wahlestedt (Claes M.D., Ph.D.)
2.80M
8.14%
-188.29K
-6.29%
Nov 25, 2025
Hayward (Marshall A Ph.D.)
2.38M
6.91%
--
--
Nov 25, 2025
Brothers (Shaun P.)
1.70M
4.94%
+188.29K
+12.46%
Nov 25, 2025
Vestor Capital Partners, LLC
970.99K
2.82%
+970.99K
--
Sep 30, 2025
Rosen (Alexander Gustaf Erik)
452.86K
1.32%
--
--
Nov 25, 2025
The Vanguard Group, Inc.
215.83K
0.63%
+215.83K
--
Sep 30, 2025
Silva (Alison D)
112.78K
0.33%
--
--
Nov 25, 2025
Geode Capital Management, L.L.C.
103.81K
0.3%
+87.95K
+554.57%
Sep 30, 2025
Elmasri (Saleem C)
66.29K
0.19%
--
--
Nov 25, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
